This HTML5 document contains 74 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n15http://linked.opendata.cz/resource/drugbank/drug/DB00405/identifier/chebi/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00405/identifier/wikipedia/
n6http://linked.opendata.cz/resource/drugbank/mixture/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00405/identifier/pharmgkb/
n17http://bio2rdf.org/drugbank:
n19http://linked.opendata.cz/resource/drugbank/drug/DB00405/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00405/identifier/pubchem-substance/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00405/identifier/drugbank/
n13http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00405/identifier/chemspider/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00405
rdf:type
n3:Drug
n3:description
Dexbrompheniramine maleate is an antihistamine used to treat allergic conditions such as hay fever or urticaria.
n3:group
approved
n3:halfLife
25 hours
n3:indication
For treatment and relief of symptoms of allergies, hay fever, and colds
n3:manufacturer
n9:271B454A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n13:DB00405 n17:DB00405
dcterms:title
Dexbrompheniramine
adms:identifier
n11:Dexbrompheniramine n14:PA164746251 n15:59269 n16:16068 n18:46505186 n19:16960 n20:DB00405
n3:mechanismOfAction
Dexbrompheniramine competitively binds to the histamine H<sub>1</sub>-receptor. It competes with histamine for the normal H<sub>1</sub>-receptor sites on effector cells of the gastrointestinal tract, blood vessels and respiratory tract. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
n3:packager
n9:271B4549-363D-11E5-9242-09173F13E4C5
n3:synonym
3-(4-bromophenyl)- N,N-dimethyl- 3-pyridin-2-yl-propan-1-amine Dexbrompheniraminum Dexbromfeniramina (+)-Brompheniraminum Desbrofeniramina Dexbromphéniramine Parabromodylamine Dexbrompheniramin (R)-3-(4-Bromophenyl)-3-(2-pyridyl)propyldimethylamine (S)-Brompheniramine (+)-parabromdylamine D-Brompheniramine (S)-(+)-Brompheniramine
n3:toxicity
Signs of an overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness.
n3:mixture
n6:271B4544-363D-11E5-9242-09173F13E4C5 n6:271B4545-363D-11E5-9242-09173F13E4C5 n6:271B4542-363D-11E5-9242-09173F13E4C5 n6:271B4543-363D-11E5-9242-09173F13E4C5 n6:271B4548-363D-11E5-9242-09173F13E4C5 n6:271B4546-363D-11E5-9242-09173F13E4C5 n6:271B4547-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Walter, L.A.; U.S. Patents 3,061,517; October 30, 1962; and 3,030,371; April 17, 1962; both assigned to Schering Corporation.
n22:hasConcept
n23:M0064163
n3:IUPAC-Name
n4:271B4550-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4556-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4555-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4552-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4553-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4554-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B454E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4566-363D-11E5-9242-09173F13E4C5 n4:271B454F-363D-11E5-9242-09173F13E4C5 n4:271B454C-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B454D-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:R06AB06
n3:H-Bond-Acceptor-Count
n4:271B455C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B455D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4557-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4558-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B455A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4559-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B455B-363D-11E5-9242-09173F13E4C5
n3:absorption
Antihistamines are well absorbed from the gastrointestinal tract after oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
132-21-8
n3:category
n3:containedIn
n21:271B454B-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4561-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4563-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4564-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4565-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4560-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B455F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4562-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4551-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B455E-363D-11E5-9242-09173F13E4C5